277 related articles for article (PubMed ID: 29894722)
1. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
2. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
3. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
4. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
5. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
6. High frequency of p16 and SOX10 coexpression but not androgen receptor expression in triple-negative breast cancers.
Yoon EC; Wilson P; Zuo T; Pinto M; Cole K; Harigopal M
Hum Pathol; 2020 Aug; 102():13-22. PubMed ID: 32565323
[TBL] [Abstract][Full Text] [Related]
7. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
[TBL] [Abstract][Full Text] [Related]
8. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
9. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma.
Bradt A; Jing X; Smola BS; Lew M
Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248
[TBL] [Abstract][Full Text] [Related]
10. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
Chiu K; Ionescu DN; Hayes M
Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273
[TBL] [Abstract][Full Text] [Related]
11. [Expression of SOX10 and GATA3 in breast cancer and their significance].
Liu JL; Chen DS; Cheng ZQ; Hu JT
Zhonghua Bing Li Xue Za Zhi; 2022 Jun; 51(6):536-541. PubMed ID: 35673726
[No Abstract] [Full Text] [Related]
12. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
14. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of Sox10 expression in triple-negative breast carcinoma.
Jin L; Qin C; Qi X; Hong T; Yang X; Zhu X
Transl Cancer Res; 2020 Sep; 9(9):5603-5613. PubMed ID: 35117924
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical Profile of Triple-Negative Breast Cancers: SOX10 and AR Dual Negative Tumors Have Worse Outcomes.
Rammal R; Goel K; Motanagh SA; Carter GJ; Clark BZ; Fine JL; Harinath L; Villatoro TM; Yu J; Bhargava R
Mod Pathol; 2024 May; 37(7):100517. PubMed ID: 38763422
[TBL] [Abstract][Full Text] [Related]
17. Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H; Tong K; Tsang JY; Ko CW; Tam F; Loong TC; Tse GM
ESMO Open; 2024 Apr; 9(4):102993. PubMed ID: 38613910
[TBL] [Abstract][Full Text] [Related]
18. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin.
Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G
Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of combined application of GATA3, SOX10 and p16 in triple negative breast carcinomas].
Zhang DM; Zhai CJ; Feng XD; Wang CZ; Qiu JF; Wei JG
Zhonghua Yi Xue Za Zhi; 2022 Mar; 102(10):735-740. PubMed ID: 35280018
[No Abstract] [Full Text] [Related]
20. SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer.
Klaric KA; Riaz N; Asleh K; Wang XQ; Atalla T; Strickland S; Nielsen TO; Kos Z
Histopathology; 2022 Feb; 80(3):589-597. PubMed ID: 34725848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
